Savara Inc. (NASDAQ:SVRA) Receives $9.13 Average Target Price from Analysts

Savara Inc. (NASDAQ:SVRA) has earned a consensus recommendation of “Moderate Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $9.1250.

SVRA has been the subject of several research analyst reports. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. Wells Fargo & Company upped their price target on shares of Savara from $7.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, December 18th. Lifesci Capital upgraded shares of Savara to a “strong-buy” rating in a research report on Tuesday, October 14th. JMP Securities boosted their target price on shares of Savara from $8.00 to $11.00 and gave the stock a “market outperform” rating in a report on Thursday, October 23rd. Finally, Citigroup reissued an “outperform” rating on shares of Savara in a research note on Thursday, October 23rd.

Hedge Funds Weigh In On Savara

Hedge funds have recently modified their holdings of the stock. Rhumbline Advisers lifted its holdings in shares of Savara by 8.6% during the first quarter. Rhumbline Advisers now owns 153,542 shares of the company’s stock valued at $425,000 after purchasing an additional 12,117 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in Savara by 17.6% during the 2nd quarter. Farther Finance Advisors LLC now owns 38,001 shares of the company’s stock worth $87,000 after buying an additional 5,687 shares during the period. May Hill Capital LLC purchased a new stake in Savara during the second quarter valued at about $32,000. Emerald Advisers LLC boosted its holdings in shares of Savara by 14.4% in the second quarter. Emerald Advisers LLC now owns 3,534,368 shares of the company’s stock worth $8,058,000 after buying an additional 444,155 shares during the period. Finally, Emerald Mutual Fund Advisers Trust boosted its holdings in shares of Savara by 8.5% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 2,186,404 shares of the company’s stock worth $4,985,000 after buying an additional 171,948 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Price Performance

Shares of SVRA stock traded down $0.06 during midday trading on Friday, reaching $5.82. 1,654,312 shares of the company were exchanged, compared to its average volume of 1,810,270. The company’s 50 day moving average price is $5.74 and its two-hundred day moving average price is $4.11. The company has a market cap of $1.18 billion, a P/E ratio of -10.98 and a beta of 0.28. Savara has a 12 month low of $1.89 and a 12 month high of $7.01. The company has a debt-to-equity ratio of 0.32, a quick ratio of 7.65 and a current ratio of 7.65.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). On average, sell-side analysts expect that Savara will post -0.45 earnings per share for the current year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.